Your browser is no longer supported. Please, upgrade your browser.
Settings
KMPH KemPharm, Inc. daily Stock Chart
KMPH [NASD]
KemPharm, Inc.
Index- P/E- EPS (ttm)-3.83 Insider Own18.99% Shs Outstand24.24M Perf Week-3.86%
Market Cap60.36M Forward P/E- EPS next Y-1.91 Insider Trans102.05% Shs Float21.19M Perf Month-49.95%
Income-56.80M PEG- EPS next Q-0.77 Inst Own26.30% Short Float5.45% Perf Quarter-46.45%
Sales- P/S- EPS this Y-161.70% Inst Trans0.16% Short Ratio5.33 Perf Half Y-59.18%
Book/sh-5.45 P/B- EPS next Y45.40% ROA-120.50% Target Price11.33 Perf Year-35.32%
Cash/sh1.16 P/C2.14 EPS next 5Y- ROE84.40% 52W Range2.44 - 8.40 Perf YTD-38.52%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.60% Beta0.41
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low1.23% ATR0.31
Employees32 Current Ratio1.80 Sales Q/Q- Oper. Margin- RSI (14)20.97 Volatility6.99% 7.26%
OptionableYes Debt/Eq- EPS Q/Q-46.70% Profit Margin- Rel Volume1.40 Prev Close2.49
ShortableYes LT Debt/Eq- EarningsNov 08 AMC Payout- Avg Volume216.46K Price2.47
Recom1.70 SMA20-32.57% SMA50-43.49% SMA200-55.21% Volume232,706 Change-0.80%
Sep-21-18Resumed Oppenheimer Outperform
Feb-26-18Reiterated Canaccord Genuity Buy $7 → $11
Jun-28-17Initiated ROTH Capital Buy $8
May-06-16Reiterated RBC Capital Mkts Outperform $22 → $14
Sep-18-15Reiterated Oppenheimer Outperform $20 → $28
Aug-14-15Reiterated RBC Capital Mkts Outperform $18 → $22
Jun-15-15Reiterated Canaccord Genuity Buy $18 → $22
May-11-15Initiated RBC Capital Mkts Outperform $18
May-11-15Initiated Canaccord Genuity Buy $18
Oct-11-18 04:05PM  KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape GlobeNewswire
Oct-05-18 10:01AM  Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings MarketWatch -36.36%
09:24AM  KemPharm Announces Pricing of Public Offering of Common Stock GlobeNewswire
Oct-04-18 04:07PM  KemPharm Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-03-18 04:41PM  KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape GlobeNewswire
Sep-17-18 07:30AM  KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug GlobeNewswire -5.83%
Sep-12-18 10:12AM  KemPharm Posts Positive Top-Line Results on KP415 Prodrug Zacks +6.19%
Sep-11-18 07:30AM  KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug GlobeNewswire -7.18%
Sep-05-18 07:30AM  KemPharm to Present at Two Healthcare Investor Conferences During September 2018 GlobeNewswire
Aug-09-18 04:05PM  KemPharm, Inc. Reports Second Quarter 2018 Results GlobeNewswire
Aug-01-18 07:30AM  KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference GlobeNewswire +7.32%
Jul-31-18 07:30AM  KemPharm, Inc. to Report Second Quarter 2018 Results GlobeNewswire +5.13%
Jul-17-18 08:41AM  Options Traders Expect Huge Moves in KemPharm (KMPH) Stock Zacks
Jul-10-18 10:37AM  KemPharm Stock Down Despite Positive Data on ADHD Candidate Zacks -11.20%
Jul-09-18 12:46PM  Groupon may be looking for a buyer, Boeing strikes major deal, KemPharm soars on drug test results Yahoo Finance Video -7.41%
11:42AM  KemPharm's ADHD Candidate Meets Efficacy, Safety Trial Endpoints Benzinga
08:31AM  Trump to reshape Supreme Court for decades to come Yahoo Finance Video
07:20AM  Yahoo Finance Live: Market Movers - Jul 9th, 2018 Yahoo Finance Video
07:13AM  KemPharm's stock soars after ADHD drug trial meets primary endpoints MarketWatch
07:00AM  KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD GlobeNewswire
May-23-18 12:00PM  Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst Benzinga
May-18-18 11:07AM  Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)? Simply Wall St.
May-11-18 01:40PM  KemPharm Stock Breaks Out on Clinical Trial Results Investopedia +11.32%
May-10-18 09:07PM  Will KemPharm Incs (NASDAQ:KMPH) Earnings Grow Over The Next Few Years? Simply Wall St.
04:05PM  KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results GlobeNewswire
May-01-18 07:30AM  KemPharm, Inc. to Report First Quarter 2018 Results GlobeNewswire
Apr-23-18 07:30AM  Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine ACCESSWIRE
Mar-29-18 08:47PM  Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH) Simply Wall St.
04:05PM  KemPharm Reports Fourth Quarter and Year End 2017 Results GlobeNewswire
12:00PM  KemPharm, Inc. to Host Earnings Call ACCESSWIRE
Mar-21-18 07:30AM  KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results GlobeNewswire +14.29%
Mar-20-18 07:30AM  KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD GlobeNewswire +6.06%
Mar-06-18 07:30AM  KemPharm to Present at Upcoming Investor Conferences GlobeNewswire
Mar-05-18 04:35PM  At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy? Simply Wall St.
Feb-26-18 10:06AM  Heres Whats Moving KemPharm And Puma Biotechnology Market Exclusive
Feb-23-18 03:38PM  KemPharm's opioid painkiller gets FDA approval, shares soar Reuters +14.03%
02:00PM  FDA approves KemPharm's opioid painkiller Reuters
02:00PM  KemPharm Announces FDA Approval of Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain GlobeNewswire
Feb-19-18 03:31PM  Why KemPharm Incs (NASDAQ:KMPH) CEO Salary Matters To You Simply Wall St.
Feb-13-18 07:30AM  KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
Jan-31-18 07:30AM  KemPharm to Present at The MoneyShow Orlando Investor Conference GlobeNewswire +7.76%
Jan-25-18 07:50AM  Blog Exposure - KemPharm Announces Patent Grant for KP606 and KP511-Related Family ACCESSWIRE
Jan-23-18 07:30AM  KemPharm Receives Patent Grant for KP606, a Prodrug of Oxycodone GlobeNewswire
Jan-08-18 07:30AM  KemPharm Initiates Pivotal Efficacy Trial of KP415 GlobeNewswire +6.18%
Dec-12-17 02:14PM  Should You Be Concerned About KemPharm Incs (undefined:KMPH) Investors? Simply Wall St.
Nov-16-17 07:30AM  KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA GlobeNewswire
Nov-09-17 04:05PM  KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update GlobeNewswire
08:15AM  How Much is KemPharm Incs (KMPH) CEO Getting Paid? Simply Wall St.
Nov-06-17 07:30AM  KemPharm Receives USAN Approval for Asalhydromorphone as Nonproprietary Name for Novel Prodrug Candidate, KP511 GlobeNewswire
Nov-02-17 07:30AM  KemPharms KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies GlobeNewswire
Nov-01-17 04:30PM  KemPharm, Inc. to Report Third Quarter 2017 Results GlobeNewswire -5.26%
Oct-06-17 07:00AM  Featured Company News - KemPharm Signs Technology Licensing Agreement with Genco to Develop Prodrug-Based Therapy for Pediatric Indications of Tourettes syndrome with ADHD ACCESSWIRE -7.93%
Oct-04-17 07:30AM  KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourettes Syndrome with ADHD GlobeNewswire
Sep-20-17 07:30AM  KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate GlobeNewswire
Sep-12-17 07:15AM  KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz NDA GlobeNewswire
Aug-31-17 07:30AM  KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire +5.17%
Aug-10-17 04:05PM  KemPharm, Inc. Reports Second Quarter 2017 Results GlobeNewswire
02:00PM  Investor Network: KemPharm, Inc. to Host Earnings Call ACCESSWIRE
07:30AM  KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial GlobeNewswire
Aug-08-17 07:30AM  KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety GlobeNewswire
Aug-03-17 07:30AM  KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Aug-01-17 07:30AM  KemPharm, Inc. to Report Second Quarter 2017 Results GlobeNewswire
Jun-29-17 10:40AM  KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline Zacks +5.63%
Jun-28-17 07:30AM  KemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate GlobeNewswire
Jun-26-17 04:05PM  KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone GlobeNewswire
Jun-09-17 07:30AM  KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids GlobeNewswire
Jun-01-17 07:30AM  KemPharm Announces Addition to Leadership Team GlobeNewswire
May-10-17 04:05PM  KemPharm, Inc. Reports First Quarter 2017 Results GlobeNewswire
10:00AM  Investor Network: KemPharm, Inc. to Host Earnings Call Accesswire
May-01-17 07:30AM  KemPharm, Inc. to Report First Quarter 2017 Results GlobeNewswire -6.52%
Mar-28-17 04:28PM  KEMPHARM, INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits +12.79%
Mar-27-17 07:30AM  KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum GlobeNewswire
Mar-16-17 01:04PM  KEMPHARM, INC Financials
07:30AM  KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicines Annual Meeting GlobeNewswire
Mar-15-17 10:38AM  Can The Uptrend Continue for KemPharm (KMPH)? Zacks
Mar-10-17 05:25PM  KEMPHARM, INC Files SEC form 10-K, Annual Report +11.27%
04:40PM  AbbVie Outperforms Drug Stocks On $20.5 Billion Growth View
Mar-09-17 05:19PM  KemPharma reports 4Q loss Associated Press
05:19PM  KemPharma reports 4Q loss
04:30PM  KemPharm Inc Earnings Call scheduled for 4:30 pm ET today
04:05PM  KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results GlobeNewswire
07:07AM  Q4 2016 KemPharm Inc Earnings Release - After Market Close
Feb-28-17 07:30AM  KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results GlobeNewswire
Feb-23-17 07:30AM  KemPharm Announces Additional Patent Protection for Prodrug Portfolio GlobeNewswire +6.94%
Feb-15-17 04:47PM  KEMPHARM, INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-07-17 07:30AM  KemPharm to Present at Upcoming Investor Conferences GlobeNewswire
Feb-03-17 09:03PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of KemPharm, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
05:01PM  Lifshitz & Miller LLP Announces Investigation of Dr. Reddy's Laboratories Limited, Exterran Corporation, Gigamon Inc., KemPharm, Inc., Navient Corporation, NCI, Inc., Opus Bank, PixarBio Corporation and Yahoo! Inc. PR Newswire
Jan-27-17 02:38PM  CRITICAL INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire +5.97%
12:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KemPharm, Inc. - KMPH Accesswire
Jan-23-17 03:02PM  Shareholder Alert: Lundin Law PC Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
11:37AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KemPharm, Inc. - KMPH PR Newswire
11:36AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of KemPharm, Inc. (KMPH) PR Newswire
Jan-20-17 11:11PM  KEMPHARM NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Significant Losses Investing In KemPharm, Inc. To Contact The Firm PR Newswire
04:17PM  Robbins Arroyo LLP: KemPharm, Inc. (KMPH) Misled Shareholders According to a Recently Filed Class Action Business Wire
Jan-12-17 02:34PM  KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
Jan-09-17 07:43AM  KEMPHARM, INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
07:30AM  KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain GlobeNewswire
Jan-04-17 07:33AM  KemPharm to Present at Biotech Showcase 2017 GlobeNewswire +9.23%
Dec-20-16 07:30AM  KemPharm Granted "Fast Track" Designation for KP201/IR GlobeNewswire
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder. It also provides APADAZ, an immediate-release (IR) combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. In addition, the company develops KP201/IR, an acetaminophen-free immediate-release formulation of APADAZ for treating short-term management of acute pain; and KP511/ER and KP511/IR hydromorphone product candidates for the treatment of pain. Further, it is developing KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. The company was founded in 2006 and is headquartered in Coralville, Iowa.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mickle Travis CPresident & CEOOct 12Buy2.555,00012,7641,703,117Oct 12 04:35 PM
Johnson Gordon KChief Business OfficerOct 12Buy2.611,0002,61010,000Oct 12 04:12 PM
Sangiovanni Timothy J.VP, Corporate ControllerOct 12Buy2.501,5003,7503,000Oct 15 04:28 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerOct 11Buy2.546501,6522,750Oct 11 06:52 PM
Sangiovanni Timothy J.VP, Corporate ControllerOct 11Buy2.551,5003,8251,500Oct 15 04:28 PM
Johnson Gordon KChief Business OfficerOct 10Buy2.623,0007,8479,000Oct 12 04:12 PM
Delaware Street Capital Master10% OwnerOct 05Buy3.002,000,0006,000,0004,095,914Oct 09 04:01 PM
Delaware Street Capital Master10% OwnerJul 30Buy4.00304,2831,217,1322,095,914Aug 01 04:05 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerMay 31Buy6.105253,2032,100Jun 01 04:14 PM
Cohen Daniel LEVP, Govt. & Public RelationsMay 15Buy6.454002,5801,450May 17 09:18 PM
Cohen Daniel LEVP, Govt. & Public RelationsMay 15Buy6.457,50048,34135,500May 17 09:18 PM
Thompson Danny LDirectorMar 23Option Exercise4.653,33315,49816,666Mar 27 05:22 PM
Cohen Daniel LEVP, Govt. & Public RelationsNov 27Buy3.797,50028,42332,500Nov 29 04:24 PM